Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin

  • Authors:
    • Yan Nan
  • View Affiliations

  • Published online on: September 18, 2019     https://doi.org/10.3892/or.2019.7323
  • Pages: 2087-2096
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The rate of lung cancer in tuberculosis (TB) patients is 7 to 30% higher than that in healthy individuals. Conventional chemotherapy of lung cancer shows limited efficiency due to poor tumor tissue drug accumulation and nonspecific cytotoxicity. Epidermal growth factor receptor (EGFR) is a promising target, which is overexpressed in lung carcinomas. In the present study, EGFR‑targeted nanoparticles were constructed and co‑delivered cisplatin (CDDP) and doxorubicin (DOX) for lung cancer therapy. In the present research, EGF‑PEG‑DSPE was synthesized. Then, EGFR‑targeted lipid polymeric nanoparticles (LPNs) were fabricated, which consisted of a CDDP‑loaded hybrophobic polymeric core, a DOX‑loaded phospholipid layer, and an outer layer of EGF‑PEG‑DSPE ligand. The particle size, ζ potential, stability, release behavior of LPNs were characterized. The antitumor ability of LPNs were assessed in vitro and in vivo. EGFR‑targeted LPNs loaded with CDDP and DOX (EGF C/D LPNs) had a size of 141.6 nm, and could encapsulate over 80% of feed drugs. Dual drug‑loaded LPNs showed synergistic effects with a combination index (CI) of 0.57. EGF C/D LPNs showed the smallest tumor volume (253 mm3), with a tumor inhibition ratio of 74.5%. In summary, EGF C/D LPNs were stable and released the drugs in a sustained manner. In vitro and in vivo studies revealed that EGF C/D LPNs exhibited improved anticancer activity along with lower toxicity. These results indicated the best efficiency of EGF C/D LPNs for lung carcinoma therapy.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 42 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nan Y: Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin. Oncol Rep 42: 2087-2096, 2019.
APA
Nan, Y. (2019). Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin. Oncology Reports, 42, 2087-2096. https://doi.org/10.3892/or.2019.7323
MLA
Nan, Y."Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin". Oncology Reports 42.5 (2019): 2087-2096.
Chicago
Nan, Y."Lung carcinoma therapy using epidermal growth factor receptor‑targeted lipid polymeric nanoparticles co‑loaded with cisplatin and doxorubicin". Oncology Reports 42, no. 5 (2019): 2087-2096. https://doi.org/10.3892/or.2019.7323